Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 23.1 26.6 87.2% View Chart
P/BV x 2.4 2.3 103.1% View Chart
Dividend Yield % 0.7 0.7 97.6%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
SUN PHARMA
Mar-19
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs678679 99.9%   
Low Rs484375 128.9%   
Sales per share (Unadj.) Rs198.2121.1 163.6%  
Earnings per share (Unadj.) Rs18.513.4 138.5%  
Cash flow per share (Unadj.) Rs35.020.7 169.1%  
Dividends per share (Unadj.) Rs3.002.75 109.1%  
Dividend yield (eoy) %0.50.5 99.0%  
Book value per share (Unadj.) Rs186.3172.6 108.0%  
Shares outstanding (eoy) m805.702,399.26 33.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.4 67.4%   
Avg P/E ratio x31.439.4 79.6%  
P/CF ratio (eoy) x16.625.5 65.2%  
Price / Book Value ratio x3.13.1 102.1%  
Dividend payout %16.220.6 78.8%   
Avg Mkt Cap Rs m468,0311,264,650 37.0%   
No. of employees `00022.617.5 129.4%   
Total wages/salary Rs m28,56559,671 47.9%   
Avg. sales/employee Rs Th7,053.116,608.1 42.5%   
Avg. wages/employee Rs Th1,261.53,409.6 37.0%   
Avg. net profit/employee Rs Th659.11,833.8 35.9%   
INCOME DATA
Net Sales Rs m159,710290,659 54.9%  
Other income Rs m4,76610,255 46.5%   
Total revenues Rs m164,475300,914 54.7%   
Gross profit Rs m30,97363,076 49.1%  
Depreciation Rs m13,26317,533 75.6%   
Interest Rs m1,6845,553 30.3%   
Profit before tax Rs m20,79150,246 41.4%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m5,6956,009 94.8%   
Profit after tax Rs m14,92432,093 46.5%  
Gross profit margin %19.421.7 89.4%  
Effective tax rate %27.412.0 229.1%   
Net profit margin %9.311.0 84.6%  
BALANCE SHEET DATA
Current assets Rs m124,266310,692 40.0%   
Current liabilities Rs m37,715173,396 21.8%   
Net working cap to sales %54.247.2 114.7%  
Current ratio x3.31.8 183.9%  
Inventory Days Days9199 91.5%  
Debtors Days Days95112 85.0%  
Net fixed assets Rs m105,190232,477 45.2%   
Share capital Rs m1,6112,399 67.2%   
"Free" reserves Rs m148,511411,691 36.1%   
Net worth Rs m150,123414,091 36.3%   
Long term debt Rs m38,30115,226 251.5%   
Total assets Rs m239,633646,938 37.0%  
Interest coverage x13.310.0 132.8%   
Debt to equity ratio x0.30 693.9%  
Sales to assets ratio x0.70.4 148.3%   
Return on assets %6.95.8 119.1%  
Return on equity %9.97.8 128.3%  
Return on capital %11.810.2 116.4%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41066,025 87.0%   
Fx outflow Rs m19,04138,610 49.3%   
Net fx Rs m38,36827,415 140.0%   
CASH FLOW
From Operations Rs m16,91121,965 77.0%  
From Investments Rs m-16,687-6,813 244.9%  
From Financial Activity Rs m-3,487-27,305 12.8%  
Net Cashflow Rs m-3,451-8,442 40.9%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 14, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS